RSL3 (a GPX4 inhibitor) inactivates GPX4 and induces glycolytic dysfunction in glioma cells with reduced ATP and pyruvate content as well as HKII, PFKP, and PKM2 protein levels, which in turn induces ferroptosis (15). The gene discussed is GPX4; the disease is central nervous system cancer.